A phase III, double-blind, randomised placebo-controlled study to evaluate the effects of Dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The Dal-GeneE trial.
Trial objective: The primary objective of this trial is to evaluate the potential of dalcetrapib to reduce cardiovascular morbidity and mortality (cardiovascular death, resuscitated cardiac arrest, nonfatal myocardial infarction (MI) and non-fatal stroke) in subjects with a documented recent ACS and the AA genotype at variant rs1967309 in the ADCY9 gene.Disease area: Cardiovascular- Post MIStatus: Closed to recruitmentCI/PI: Prof Colin Berry/ Dr David CollierSponsor: MedpaceFunder: Dal Cor Pharma UK Limited
Reduction of cardiovascular mortality and morbidity in subjects with a documented recent Acute Coronary Syndrome (ACS) and the AA genotype at variant rs1967309 in the adenylate cyclase type 9 (ADCY9) gene.
5000 internationally.This study is an event-driven study and will last until approximately 434 primary events have occurred. The estimated total duration is approximately 54 months including enrolment and follow-up.
Ania Michalska, Senior Research NurseTel: +44(0) 20 7882 5665Email: firstname.lastname@example.org